Sanofi is shifting the focus of diabetes care toward early intervention and the preservation of insulin-producing cells. Their breakthrough therapy, teplizumab (Tzield), is the first of its kind to delay the onset of clinical Type 1 diabetes by targeting the immune system before the pancreas is fully compromised. This matters because it provides a critical window of time, often years without the burden of insulin injections, while also reducing the risk of life-threatening complications like DKA. By championing widespread screening and immune-based therapy, Sanofi is moving the needle from just managing symptoms to fundamentally altering the disease’s progression.